Evidence map›Paper›PMID 39854377›Full record

ArticlePloS one2025

Machine learning model to predict the adherence of tuberculosis patients experiencing increased levels of liver enzymes in Indonesia.

Dyah Aryani Perwitasari, Imaniar Noor Faridah, Haafizah Dania, Didik Setiawan, Triantoro Safaria

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dyah Aryani PerwitasariFaculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.ORCID 0000-0002-2638-6664
Imaniar Noor FaridahFaculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.
Haafizah DaniaFaculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.
Didik SetiawanFaculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Purwokerto, Indonesia.ORCID 0000-0001-9104-548X
Triantoro SafariaFaculty of Psychology, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indonesia is still the second-highest tuberculosis burden country in the world. The antituberculosis adverse drug reaction and adherence may influence the success of treatment. The objective of this study is to define the model for predicting the adherence in tuberculosis patients, based on the increased level of liver enzymes. The longitudinal study using adult tuberculosis patients treated with the first line of antituberculosis was conducted prospectively. The pregnant women and patients with complications such as gout, diabetes mellitus, liver disorder and HIV were excluded. We measured the total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) and adherence over the 2nd, 4th, and 6th months of the treatment. We used the ORANGE Data mining as the machine learning to predict the adherence. We recruited 201 patients, whereas the male participants and less than 61 years old as the dominant participants. Around 33%, 35% and 35% tuberculosis patients experienced the increase level of bilirubine, ALT and AST, respectively. There were significant differences in ALT and AST between good and poor adherence groups, especially in the female patients. The Neural Network and Random Forests were the most suitable models to predict tuberculosis patients' adherence with good Area Under The Curve (AUC).

Indexed as

Antitubercular AgentsLiverMachine LearningMedication AdherenceTuberculosisAdultAlanine TransaminaseAspartate AminotransferasesBilirubinFemaleHumansIndonesiaLongitudinal StudiesMaleMiddle AgedProspective StudiesAlanine TransaminaseAntitubercular AgentsAspartate AminotransferasesBilirubin

Identifiers

PMID39854377
PMCPMC11760577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.